Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled with metformin. RESEARCH DESIGN AND METHODS: Adults with diabetes inadequately controlled (HbA1c 7–10%) with metformin were randomized to lixisenatide 20 μg once daily (n = 318) or exenatide 10 μg twice daily (n = 316) in a 24-week (main period), open-label, parallel-group, multicenter study. The primary objective was a noninferiority assessment of lixisenatide versus exenatide in HbA1c change from baseline to week 24. RESULTS: Lixisenatide once daily demonstrated noninferiority in HbA1c reduction versus exenatide twice daily. The least squares mean change was −0.79% (mean decrease 7.97 to 7.17%) for lixisenatide versus −0.96% (mean decrease 7.96 to 7.01%) for exenatide, and treatment difference was 0.17% (95% CI, 0.033–0.297), meeting a predefined noninferiority upper CI margin of 0.4%. Responder rate (HbA1c <7.0%) and improvements in fasting plasma glucose were comparable. Both agents induced weight loss (from 94.5 to 91.7 kg and from 96.7 to 92.9 kg with lixisenatide and exenatide, respectively). Incidence of adverse events (AEs) was similar for lixisenatide and exenatide, as was incidence of serious AEs (2.8 and 2.2%, respectively). Discontinuations attributable to AEs occurred in 33 lixisenatide (10.4%) and 41 exenatide (13.0%) patients. In the lixisenatide group, fewer participants experienced symptomatic hypoglycemia (2.5 vs. 7.9%; P < 0.05), with fewer gastrointestinal events (especially nausea; 24.5 vs. 35.1%; P < 0.05). CONCLUSIONS: Add-on lixisenatide once daily in type 2 diabetes inadequately controlled with metformin demonstrated noninferior improvements in HbA1c, with slightly lower mean weight loss, lower incidence of hypoglycemia, and better gastrointestinal tolerability compared with exenatide twice daily.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared with EX, the frequency of subcutaneous injection of LIXI is less, and the incidence of gastrointestinal adverse reactions and hypoglycemia is lower. Compared with LIXI, LIR is more effective in improving blood glucose and reducing weight, and both treatments are well tolerated (75, 77, 78).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“tric emptying, and are associated with beneficial effects on weight and appetite reduction (9).”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“(27), exenatide 10 mg twice daily reduced HbA1c by 0.”
BackgroundResultBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“Higher rates have been reported in studies with other background therapies (51% in combination with a sulfonylurea) (32,33).”
ResultSelf-citationNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942 · cited 1×
“GLP-1 receptor agonists increasingly have become established as effective therapeutic options in type 2 diabetes management (6,7).”
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Self-citation
Research works printed but not linked: 2
- Bolli, 2011, Efficacy and safety of lixisenatide once-daily versus placebo in patients with T2DM insufficiently controlled on metformin (GetGoal-F1). Poster presented at 47th Annual Meeting of the European Association for the Study of Diabetes, 12–16 September 2011, Lisbon, Portugal, Diabetologia, 54, 1
- Riddle, 2013, 36, 2489
Cited by
Items 101–200 of 251
Incretin-based therapies for obesity treatment
de Mello, A. H., Prá, M. D., Cardoso, L. C., Schraiber, R. D. B., & Rezin, G. T. (2015) · Metabolism · doi:10.1016/j.metabol.2015.05.012 · Cited by 36
“Another study comparing lixisenatide versus exenatide BID as an addition to metformin showed that lixisenatide was less effective in weight loss, but had a more favorable gastrointestinal tolerability than exenatide BID [76].”
BackgroundPrevention of type 2 Diabetes Mellitus: Potential of pharmacological agents
Samson, S. L., & Garber, A. J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.005 · Cited by 37
GLP-1 receptor agonists: differentiation within the class
Taylor, S. I. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30413-8 · Cited by 37
CNS-targeting pharmacological interventions for the metabolic syndrome
Stemmer, K., Müller, T. D., DiMarchi, R. D., Pfluger, P. T., & Tschöp, M. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129195 · Cited by 36
“(once daily), 10 μg or 20 μg GetGoal-X (24-week trial in inadequately controlled T2D patients, 20 μg once daily) (191); HbA1c reduction from baseline: –0.”
BackgroundReaney, M. D., Elash, C. A., & Litcher‐Kelly, L. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.009 · Cited by 37
Li, Z., Zhang, Y., Quan, X., Yang, Z., Zeng, X., Ji, L., Sun, F., & Zhan, S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154206 · Cited by 33
Åhrén, B., Gautier, J., Berria, R., Stager, W., Aronson, R., & Bailey, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12290 · Cited by 33
Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes
Lau, D. C. W., & Teoh, H. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.090 · Cited by 34
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
Rameshrad, M., Razavi, B. M., Lalau, J., Broe, M. E. D., & Hosseinzadeh, H. (2020) · PubMed Central · doi:10.22038/ijbms.2020.41638.9832 · Cited by 41
Combining a GLP-1 Receptor Agonist and Basal Insulin: Study Evidence and Practical Considerations
Carris, N. W., Taylor, J. R., & Gums, J. G. (2014) · Drugs · doi:10.1007/s40265-014-0325-2 · Cited by 28
“Compared with twice-daily exenatide, lixisenatide produced a numerically greater but statistically non-inferior reduction in HbA1c, but less weight loss [46].”
BackgroundBain, S. C. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0073-z · Cited by 29
Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus
Khan, M. A., Ouyang, J., Perkins, K., Nair, S., & Joseph, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/162718 · Cited by 32
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 39
Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management
McCarty, D., Coleman, M., & Boland, C. L. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017689878 · Cited by 27
“Pharmacodynamic studies suggest that lixisenatide may have more benefit in reducing PPG than FPG when compared with once-daily liraglutide.28 Lixisenatide reduced PPG significantly more than liraglutide following a standardized breakfast: −227 versus −72 mg/dL, respectively (P < 0.0001).28 Additionally, the incidence…”
BackgroundMethodInfluentialAre peptide conjugates the golden therapy against obesity?
Brandt, S. J., Kleinert, M., Tschöp, M. H., & Müller, T. D. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0264 · Cited by 27
Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
Forst, T., & Pfützner, A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.838559 · Cited by 25
Becker, R. H. A., Stechl, J., Msihid, J., & Kapitza, C. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12278 · Cited by 25
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Bahtiyar, G., Pujals-Kury, J., & Sacerdote, A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1043-z · Cited by 24
Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Scott, L. J. (2013) · BioDrugs · doi:10.1007/s40259-013-0057-y · Cited by 26
“The primary efficacy endpoint was the noninferiority of lixisenatide to exenatide in terms of the absolute change from baseline in HbA1c levels at 24 weeks [33].”
BackgroundInfluentialSafety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues
Raccah, D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1268598 · Cited by 24
Self-citationPharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon
Sekar, R., Singh, K., Arokiaraj, A. W. R., & Chow, B. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.002 · Cited by 27
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Ni, X., Zhang, L., Feng, X., & Tang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877797 · Cited by 26
Ren, X., Hua, H., Wu, Y., Zhang, W., Long, X., Bai, Y., & Cheng, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-09807-0 · Cited by 38
Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment
Hanefeld, M., Arteaga, J. M., Leiter, L. A., Marchesini, G., Nikonova, E., Shestakova, M., Stager, W., & Gómez‐Huelgas, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12986 · Cited by 22
Trujillo, J. M., & Goldman, J. D. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1962 · Cited by 22
Umpierrez, G. E., Bailey, T. S., Carcia, D., Shaefer, C. F., Shubrook, J. H., & SKOLNIK, N. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12576 · Cited by 25
Giorgino, F., Bonadonna, R., Gentile, S., Vettor, R., & Pozzilli, P. (2016) · Diabetes/Metabolism Research Reviews · doi:10.1002/dmrr.2775 · Cited by 17
Ji, Q. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.013 · Cited by 24
Lixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes.
Leon, N., LaCoursiere, R. J., Yarosh, D., & Patel, R. S. (2017) · PubMed · Cited by 35
An, X., Sun, W., Wen, Z., Duan, L., Zhang, Y., Kang, X., Ji, H., Sun, Y., Jiang, L., Zhao, X., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16228 · Cited by 25
Hunt, B., Ye, Q., Valentine, W. J., & Ashley, D. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0219-2 · Cited by 22
Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes
Hedrington, M. S., Tsiskarishvili, A., & Davis, S. N. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1439014 · Cited by 20
Glucagon-like Peptide-1 Agonists: What the Orthopaedic Surgeon Needs to Know
Chan, P. Y. W., Mika, A. P., Martin, J. R., & Wilson, J. M. (2024) · JBJS Reviews · doi:10.2106/jbjs.rvw.23.00167 · Cited by 21
Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day
Ahrén, B., Vorokhobina, N., Souhami, E., Demil, N., Ye, J., & Aronson, R. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.05.012 · Cited by 19
Yabe, D., Ambos, A., Cariou, B., Duvnjak, L. S., Evans, M., González-Gálvez, G., Lin, J., Nikonova, E. V., de Pablos-Velasco, P. L., Yale, J., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.018 · Cited by 18
“Reports from the lixisenatide clinical trial programme suggest that lixisenatide is associated with a generally low risk of hypoglycaemia [12,22], probably because the effects of lixisenatide on insulin secretion are glucose-dependent.”
BackgroundSeino, Y., Yabe, D., Takami, A., Niemoeller, E., & Takagi, H. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.07.003 · Cited by 18
“…program, in which it was shown to be efficacious and well tolerated in patients with T2DM (Ahren et al., 2013; Fonseca et al., 2012; Pinget et al., 2013; Riddle, Aronson, et al., 2013; Riddle, Forst, et al., 2013; Rosenstock et al., 2013; Seino, Min, Niemoeller, Takami, & Investigators, 2012).”
BackgroundHan, J. D. J., Zhou, F. L., Fei, Y., Chen, X., Fu, J., & Qian, H. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00712 · Cited by 18
Kang, Y. M., Punov, V., Lim, S., & Nauck, M. A. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16398 · Cited by 20
“10 Subsequent development of long-acting GLP-1 RAs aimed to provide stable pharmacokinetic profiles without troughs over a ≥ 24-h period post administration.”
InfluentialHarnessing GLP‐1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon
Abdelrahman, R. M., Musa, T. H., Arbab, I. A., Suliman, M. H., Ahmed, E. O., Mohamed, A. N., Musa, H. H., Jalal, M., & Gasmallah, S. I. (2025) · Journal of Obesity · doi:10.1155/jobe/9919810 · Cited by 24
Schneider, R., Kraljević, M., Peterli, R., Rohm, T. V., Klasen, J. M., Cavelti‐Weder, C., & Delko, T. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04750-7 · Cited by 18
Napoli, R., Avogaro, A., Formoso, G., Piro, S., Purrello, F., Targher, G., & Consoli, A. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.08.039 · Cited by 18
A Plethora of GLP-1 Agonists: Decisions About What to Use and When
Samson, S. L., & Garber, A. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0823-6 · Cited by 20
Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials
Blonde, L., Chava, P., DEX, T. A., Lin, J., Nikonova, E. V., & Goldenberg, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12815 · Cited by 15
Girges, C., Vijiaratnam, N., Athauda, D. S., Auld, G., Gandhi, S., & Foltynie, T. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00853-7 · Cited by 18
Scholz, G. H., & Fleischmann, H. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814556099 · Cited by 18
Hanefeld, M., Berria, R., Lin, J., Aronson, R., Darmon, P., Evans, M., & Gaal, L. V. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0146-4 · Cited by 18
Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes
Yabe, D., & Seino, Y. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.949672 · Cited by 16
Messak, M., Abdelmageed, A., Senbel, A. A., Khattab, Y. A., Mandour, Y., Shaker, O., Rehan, A. H., Oransa, S., Nasr, M., Shabeeb, A. E., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03932-3 · Cited by 20
“Most studies investigating GLP-1 receptors, whether as a drug for type 2 diabetes or obesity, have shown that the most common adverse events were gastrointestinal (GI) events (Dun-gan et al. 2014; Pratley et al. 2014; Rosenstock et al. 2013), which is consistent with our findings.”
Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus
Leiter, L. A., & Nauck, M. A. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-103969 · Cited by 16
Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes
Molina‐Vega, M., Muñoz‐Garach, A., & Tinahones, F. J. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1420160 · Cited by 16
Inter-relationships between gastric emptying and glycaemia: Implications for clinical practice
Murthy, T. A., Chapman, M. J., Jones, K. L., Horowitz, M., & Marathe, C. S. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i5.447 · Cited by 17
Natale, P., Green, S. C., Tunnicliffe, D. J., Pellegrino, G., Toyama, T., & Strippoli, G. F. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015849.pub2 · Cited by 40
Raccah, D., Gourdy, P., Sagnard, L., & Ceriello, A. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2548 · Cited by 14
Self-citationAlbèr, A., Brønden, A., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12911 · Cited by 14
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
Galstyan, G. R., Анатольевна, К. Е., & Александровна, Ю. Е. (2017) · Diabetes Mellitus · doi:10.14341/dm8804 · Cited by 21
Quiñones, M., Fernø, J., Diéguez, C., Nogueiras, R., & Al–Massadi, O. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1583642 · Cited by 14
“Exenatide is currently used to control glucose levels in T2DM patients; in addition, the drug has demonstrated potent weight-lowering effects in rodents, as well as a moderate weight lowering efficacy in humans [63,64].”
BackgroundOnishi, Y., Niemoeller, E., Ikeda, Y., Takagi, H., Yabe, D., & Seino, Y. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12275 · Cited by 13
Lixisenatide as add-on therapy to basal insulin
Evans, M., Butler, E. L., & Brown, D. X. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s45108 · Cited by 17
“4%.(49) Exenatide twice daily provides a good comparator for lixisenatide because they are both based on the structure of exendin-4 and are intermittent-release agents.”
Engineering PEG-fatty acid stapled, long-acting peptide agonists for G protein-coupled receptors
Lear, S., Amso, Z., & Shen, W. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.02.008 · Cited by 16
Novel Hypoglycaemic Agents: Considerations in Patients with Chronic Kidney Disease
Game, F. L. (2014) · Nephron Clinical Practice · doi:10.1159/000357680 · Cited by 12
Moore, M. C., Werner, U., Smith, M. S., Farmer, T. D., & Cherrington, A. D. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00354.2013 · Cited by 12
The role of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Onge, E. S., Miller, S. A., Clements, E. A., Celauro, L., & Barnes, K. (2017) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2017-0015 · Cited by 13
George, C. M., Byun, A., & Howard-Thompson, A. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.05.043 · Cited by 13
Pérez, M. B., Hsia, D. S., Sloan, L. A., Nell, H., Mungur, O., Hovsepian, L., Schmider, W., Spranger, R., Yang, N., & Niemoeller, E. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13343 · Cited by 14
Osumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 16
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
Davidson, J. A. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1096743 · Cited by 12
Han, J. D. J., Fu, J., Sun, L., Han, Y., Mao, Q., Liao, F., Zheng, X., & Zhu, K. (2017) · MedChemComm · doi:10.1039/c7md00471k · Cited by 10
Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy
Merlino, D. J., Blomain, E. S., Aing, A., & Waldman, S. A. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030763 · Cited by 13
Handelsman, Y., Muskiet, M. H. A., & Meneilly, G. S. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01126-x · Cited by 12
Garber, A. J. (2015) · Endocrine Practice · doi:10.4158/ep14460.ra · Cited by 12
Lixisenatide – A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes
Vidal, J. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2013.09.02.76 · Cited by 15
Sheng, L., Deng, M., Li, X., Wan, H. Y., Lei, C., Prabahar, K., Hernández‐Wolters, B., & Kord‐Varkaneh, H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111617 · Cited by 13
Fisher, M. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12380 · Cited by 11
Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease
Oikonomou, E. K., Xenou, M., Zakynthinos, G. Ε., Tsaplaris, P., Lampsas, S., Bletsa, E., Gialamas, I., Kalogeras, K. I., Goliopoulou, A., Gounaridi, M. I., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230703161058 · Cited by 12
Shi, X., Shi, Y., Chen, N., Lin, M., Su, W., Zhang, H., Liu, C., Song, H., Xiao, F., Huang, P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02631-1 · Cited by 10
Glucose-lowering treatment in cardiovascular and peripheral artery disease
Suades, R., Cosentino, F., & Badimón, L. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.03.001 · Cited by 12
Seino, Y., Terauchi, Y., Wang, X., Watanabe, D., Niemoeller, E., & the study investigators (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12646 · Cited by 7
Glucagon-like peptide-1 receptor agonists
Gallwitz, B. (2016) · Springer eBooks · doi:10.1007/978-3-319-08982-9_3 · Cited by 9
Incretin manipulation in diabetes management
Pappachan, J. M., Raveendran, A. V., & Sriraman, R. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.774 · Cited by 10
Lixisenatida en pacientes con diabetes tipo 2 y obesidad: más allá del control glucémico
Roca-Rodríguez, M. M., Muros de Fuentes, M. T., Piédrola-Maroto, G., Quesada-Charneco, M., Maraver-Selfa, S., Tinahones, F. J., & Mancha-Doblas, I. (2017) · Atención Primaria · doi:10.1016/j.aprim.2016.06.009 · Cited by 8
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Bergenstal, R. M., Strock, E. S., Mazze, R. S., Powers, M. A., Monk, A. M., Richter, S. A., Souhami, E., & Åhrén, B. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2879 · Cited by 8
Yuan, S., & Wu, Y. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1201818 · Cited by 11
Sabina, M., & Alsamman, M. (2024) · Cardiology Research · doi:10.14740/cr1600 · Cited by 10
Lixisenatide: A New Option for Managing Type 2 Diabetes
Newsome, J. S. (2017) · Journal of Pharmacy Technology · doi:10.1177/8755122517711958 · Cited by 11
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 9
Petrova, L., Andreevska, K., Parvova, I., & Petkova, V. B. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e132148 · Cited by 9
“The mean decrease in systolic pressure is -2.9 mmHg in the Lixisenatide group and -2.5 mmHg in the Exenatide group; for diastolic pressure, the mean decreases are -1.8 mmHg and -1.3 mmHg, respectively (Rosenstock et al. 2013).”
BackgroundInfluentialSpecific Activity of Recombinant Modified Human Glucagon-Like Peptide 1
Sannikova, E. P., Bulushova, N. V., Cheperegin, S. E., Zalunin, I. A., Klebanov, F. A., Gracheva, T. S., Yurin, V. L., Rykalina, N. V., Askerova, E. V., Yarotskii, S. V., et al. (2019) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683819070068 · Cited by 8
Baker, D. E., & Levien, T. L. (2017) · Hospital Pharmacy · doi:10.1310/hpj5201-65 · Cited by 6
Broglio, F., Mannucci, E., Napoli, R., Nicolucci, A., Purrello, F., Nikonova, E., Stager, W., & Trevisan, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12810 · Cited by 6
Terauchi, Y., Usami, M., & Inoue, T. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02121-5 · Cited by 7
Htike, Z., Zaccardi, F., Chatterjee, S., Khunti, K., & Davies, M. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.091 · Cited by 6
Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists
Chilton, R. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000483 · Cited by 4
Recent Trends in Peptide Drug Discovery and Development
Madge, H. Y. R., & Muttenthaler, M. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674541-00023 · Cited by 6
Seino, Y., Stjepanovic, A., Takami, A., Takagi, H., & the study investigators (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12686 · Cited by 4
Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Bala, S., Allan, K. C., Decker, N. L., Abbass, N. J., Joo, J. H., Zhao, A., Talcott, K. E., & Rachitskaya, A. V. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.12.007 · Cited by 7
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 7
Agonistas de GLP-1 en el control glucémico y ponderal de la diabetes tipo 2. Nuevas perspectivas
Alonso, S. P., Valdés, S., & Doulatram‐Gamgaram, V. K. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107042 · Cited by 4
Metadata
- Authors
- Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E.
- Affiliations
- Medical City Dallas Hospital (US)
- Hôpital Sainte-Marguerite (FR)
- DRC Ltd, Balatonfüred, Hungary
- Investigación Clinica Aplicada, Buenos Aires, Argentina
- Sanofi (France) (FR)
- University of Rochester Medicine (US)
- Corresponding author
- Rosenstock, Julio
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-09-14
- Volume
- 36
- Issue
- 10
- Pages
- 2945-2951
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3781502
- OpenAlex
- W2133648480
- Cited by
- 253
- References
- 29
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 10 · 2023: 9 · 2022: 5 · 2021: 9 · 2020: 10 · 2019: 12 · 2018: 20 · 2017: 41 · 2016: 33 · 2015: 24 · 2014: 34 · 2013: 16
- FWCI
- 28.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- exenatide, type 2 diabetes, glycemic control, metformin, GLP-1 receptor agonists, HbA1c reduction, non-inferiority, weight loss, hypoglycemia, gastrointestinal adverse effects, nausea, adjunctive therapy, once-daily dosing, twice-daily dosing, fasting blood glucose
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
